Danielle Antalffy's questions to AtriCure Inc (ATRC) leadership • Q3 2024
Question
Danielle Antalffy asked about the growth trend in the AtriClip business, questioning if the competitive impact had bottomed out and how centers are adopting multiple devices. She also inquired about the current market penetration of the EnCompass Clamp in CABG procedures.
Answer
CEO Michael H. Carrel attributed the accelerating AtriClip growth to broader market expansion driven by competition and innovation like the new FLEX-Mini. He noted that while some accounts use both AtriCure's and a competitor's device, no accounts have been lost. Regarding EnCompass, he estimated that penetration in cardiac surgery patients with Afib has increased to the 30-35% range, highlighting a substantial remaining growth opportunity based on global treatment guidelines.